Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - senshio
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp446d079a08d59e4d16270357097325eb
identifier: http://ema.europa.eu/identifier
/EU/1/14/978/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Senshio 60 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-446d079a08d59e4d16270357097325eb
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/14/978/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - senshio
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Senshio contains the active substance ospemifene. Ospemifene belongs to a group of medicines that do not contain hormones called Selective Estrogen Receptor Modulators (SERMs).
Senshio is used to treat women with moderate to severe post-menopausal symptoms in and outside the vagina, such as itching, dryness, burning and pain during sex (dyspareunia). This is known as vulvar and vaginal atrophy. It is caused by a lowering in the levels of the female hormone oestrogen in your body. When this happens, the vaginal walls can become thinner. This happens naturally after menopause (post-menopause).
Senshio works in a similar way to some of the helpful effects of oestrogen, helping to improve these symptoms and the underlying causes of vulvar and vaginal atrophy.
Do not take Senshio
Warnings and precautions
Once you have started on Senshio you should see your doctor for regular check-ups (at least once a year). At these check-ups, discuss with your doctor the benefits and risks of continuing with Senshio.
Talk to your doctor or pharmacist before taking Senshio if any of the following apply to you.
While taking Senshio:
Children and adolescents Do not give this medicine to children or adolescents. This medicine is only intended for use in post- menopausal women.
Other medicines and Senshio Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Do not take Senshio with any of these medicines:
Oestrogens.
Any other medicine belonging to the group called SERMs, such as tamoxifen, toremifene, bazedoxifene and raloxifene.
Talk to your doctor before taking Senshio with:
Fluconazole (an oral medicine used to treat fungal infections) as this may increase the amount of ospemifene in your blood. Your doctor may consider stopping treatment with Senshio while you are taking fluconazole.
Any of the following medicines, which may lead to a reduced effect of Senshio: * Rifampicin and rifabutin commonly used to treat tuberculosis. * Carbamazepine and phenytoin used to treat convulsions/seizures (anticonvulsants). * St John s wort, a herbal medicine sometimes used to treat depression. * Orlistat sometimes used to treat obesity.
Any of the following medicines, as their concentrations may be increased while taking Senshio: * Metformin used to treat Type II diabetes. * Aciclovir used to treat cold sores and genital herpes. * Ganciclovir used to treat infections caused by a virus called cytomegalovirus. * Oxaliplatin, an anti-cancer medicine for advanced (metastatic) cancer of the large bowel (colon) or back passage (rectum).
Pregnancy, breast-feeding and fertility Senshio is for use only in postmenopausal women. It must not be taken by women who are pregnant, who could still have a baby or are breast-feeding. This is because there are no data on the use of Senshio in pregnant or pre-menopausal women or those who are breast-feeding.
Tell your doctor immediately if you become pregnant while taking Senshio; treatment should be stopped immediately.
Driving and using machines Senshio has no known or very little influence on the ability to drive and use machines.
Senshio contains lactose If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. Senshio contains sodium This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose is one tablet taken orally at the same time each day. Senshio should be taken with food. The tablets should be swallowed whole with food.
Senshio must be taken every day for as long as your doctor tells you to.
Patients with liver disease This medicine is not recommended if you have severely reduced liver function.
If you take more Senshio than you should If you take more tablets than you should, tell your doctor or pharmacist.
If you forget to take Senshio If you forget to take a tablet you should take the missed tablet (with food) as soon as you remember within the same day. Do not take two tablets in one day to make up for a forgotten tablet.
If you stop using Senshio You will not benefit from the effects of Senshio if you stop using it without talking to your doctor. Your doctor will explain the effects of stopping treatment and will also discuss other possibilities for treatment with you.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP . The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Senshio contains
What Senshio looks like and contents of the pack Senshio tablets are oval biconvex, white to off-white, film-coated tablets (approximately 12 mm long by 6.45 mm wide) debossed with 60 on one side.
They are packed in blisters and are available in pack sizes of 7, 28 or 84 film-coated tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder Shionogi B.V. Herengracht 1017 CA Amsterdam Netherlands
Manufacturer Shionogi B.V. Herengracht 1017 CA Amsterdam Netherlands
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
AT, BE, BG, CY, CZ, DK, EE, IE, EL, FI, HR, HU, IE, IS, LT, LU, LV, MT, NL, NO, PL, RO, SE, SI, SK Shionogi B.V. Tel/Tel./Te ./Tlf/T l/Puh/S mi/ :
ES Shionogi SLU Tel: +34 911 239 contacta@shionogi.eu
IT Shionogi Srl Tel: +39 06 94 805 contattaci@shionogi.eu
PT Lifewell Pharmaceutical & Healthcare, Lda. Tel: +351215810info@lifewell.pt
UK (NI) Shionogi B.V. Tel +44 (0) 2891248contact@shionogi.eu
FR Shionogi SAS Tel: +33 (0) 186655contactfrance@shionogi.eu
This leaflet was last revised in
Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-446d079a08d59e4d16270357097325eb
Resource Composition:
Generated Narrative: Composition composition-en-446d079a08d59e4d16270357097325eb
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/14/978/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - senshio
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp446d079a08d59e4d16270357097325eb
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp446d079a08d59e4d16270357097325eb
identifier:
http://ema.europa.eu/identifier
/EU/1/14/978/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Senshio 60 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en